PT  - JOURNAL ARTICLE
AU  - Li, Xiao
AU  - Willem, Lander
AU  - Johannesen, Caroline Klint
AU  - Urchueguía-Fornes, Arantxa
AU  - Lehtonen, Toni
AU  - Osei-Yeboah, Richard
AU  - Salo, Heini
AU  - Sánchez, Alejandro Orrico
AU  - Domingo, Javier Díez
AU  - Jit, Mark
AU - PROMISE investigators
AU  - Bilcke, Joke
AU  - Nair, Harish
AU  - Beutels, Philippe
TI  - Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: A multi-country analysis
AID  - 10.1101/2024.08.06.24311440
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.08.06.24311440
4099  - http://medrxiv.org/content/early/2024/08/07/2024.08.06.24311440.short
4100  - http://medrxiv.org/content/early/2024/08/07/2024.08.06.24311440.full
AB  - Background We aimed to identify influential drivers of the cost-effectiveness of older adult respiratory syncytial virus (RSV) vaccination in Denmark, Finland, the Netherlands and Valencia-Spain.Methods A static multi-cohort model was parameterised using country- and age-specific hospitalisations using three approaches: (1) the International Classification of Diseases (ICD)-coded hospitalisations, (2) laboratory RSV-confirmed hospitalisations and (3) time-series modelling (TSM). Plausible hypothetical RSV vaccine characteristics were derived from two protein subunit vaccines for adults aged ≥60 years (“60y+”). Costs and quality-adjusted life-years (QALYs) were compared between four strategies: (a) “no intervention” and RSV vaccination in adults (b) 60y+; (c) 65y+; (d) 75y+, from both the healthcare payers’ and societal perspectives. Value of information, probabilistic sensitivity and scenario analyses identified influential drivers.Results Besides vaccine price, the hospitalisation estimates were most influential: Using adjusted RSV-ICD-coded hospitalisations at a vaccine price of €150 per dose, no intervention was cost-effective up to willingness-to-pay (WTP) values of €80000 per QALY gained in Denmark, and up to €34000 and €62000 per QALY gained in Finland and the Netherlands, respectively. Using the adjusted RSV-confirmed dataset, the findings were consistent in Denmark and comparable in Finland. In Spain-Valencia, the 75y+ strategy became cost-effective at WTP >€17000. Using TSM-based estimates, the 75y+ strategy was cost-effective at WTP >€16000, >€28000, >€13000 and >€37000 in Denmark, Finland, the Netherlands and Spain-Valencia, respectively. The (in-hospital) case fatality ratio and the specification of its age dependency were both influential. Specifying different ways in which protective efficacy waned and RSV seasons were shaped and timed had both relatively limited impact on results.Conclusion Data gaps and uncertainties on the RSV-related burden in older adults persists and influences the cost-effectiveness of RSV vaccination. More refined age- and country-specific data on the RSV attributable burden are crucial to aid decision making.Competing Interest StatementOutside the submitted work, PB declares funding received by his institute from Merck for research on varicella zoster and Pfizer for research on pneumococcus vaccine, XL declares funding received by her institute from Icosavax, but they have not received any personal fees or other personal benefits. CKJ reports a research grant from Nordsjallands Hospital, travel grants from the University of Copenhagen, William Demants Fond in Denmark, and the European Society of Clinical Virology and expert consultation fees from Sanofi, outside of the submitted work. Outside the submitted work, HN declares consulting fees received from WHO, Pfizer, Bill and Medlinda Bill and Melinda Gates Foundation and Sanofi, honoraria for lectures/presentations from Astra Zeneca, GSK and Pfizer paid to his institution, travel grants from Pfizer and Sanofi, and participation on a Data Safety Monitoring Board or Advisory Board of GSK, Sanofi, Merck, Icosavax, Pfizer (paid to his institution), as well as WHO and ResViNET (unpaid). AUF declares grants/contracts from Moderna and VAC4EU paid to her institution, outside submitted work. AOS and JDD declares grants/contracts from Moderna, MSD and GSK paid to their institution, outside submitted work. AOS also declares consultancy fees from GSK and Moderna, outside submitted work. JDD declares consultancy fees and honoraria from GSK, Pfizer and MSD, and travel grants from Sanofi and GSK, outside the submitted work. HS declares attending Adult Immunization Board meetings twice a year, the meetings (and travel) are funded by an unrestricted grant from Vaccines Europe, outside submitted work. LW declares grants received from Research Foundation Flanders (FWO), Antwerp University Research Council and Horizon Europe 2.1 Health paid to his institute, outside the submitted work. MJ declares research grants from NIHR, RCUK, BMGF, WHO, Gavi, Wellcome Trust, European Commission, InnoHK, TFGH, CDC, Gates Foundation paid to his institution, outside the submitted work. Other authors declared no competing interests.Funding StatementThis project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement number 101034339. The JU receives support from the European Union's Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries Associations. MJ received funding from the NIHR Health Protection Research Units in Modelling and Health Economics (NIHR200908) and Immunisation (NIHR200929). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAlmost all the data analysed and generated during this study are included in this published article and its supplementary files. Formal requests for additional data can be made to the corresponding author (XL) or the senior author (PB).ACIPAdvisory Committee on Immunization PracticesCIconfidence intervalCOVID-19coronavirus disease 2019CPIconsumer price indexEVPPIexpected value of partial perfect informationhCFRin-hospital case fatality ratioHCPhealthcare payerICDInternational Classification of DiseasesILIinfluenza-like-illnessJCVIJoint Committee on Vaccination and ImmunisationMAmedical attendanceMCMARCELAMulti-Country Model Application for RSV Cost-Effectiveness policy for AdultsPCRpolymerase chain reactionPROMISEPreparing for RSV Immunisation and Surveillance in EuropeQALYquality-adjusted life-yearsRSVrespiratory syncytial virusSARS-CoV-2severe acute respiratory syndrome coronavirus 2TSMtime-series modellingUKUnited KingdomUSUnited StatesWTPwillingness-to-payYyear